A Look at the Life and Career of Dr. Lindsay Rosenwald
As a major player in the biotechnology sector, Dr. Lindsay Rosenwald is known as a pacesetter for the latest innovations in the healthcare and biotechnology industry. His portfolio of companies ranges from promising drug companies to research companies working on exciting new cancer drugs.
As a well known Wall Street venture capitalist, Dr. Lindsay Rosenwald possesses the pioneer spirit when searching for fresh, new investment opportunities. He has a strong reputation and almost two decades of experience as a venture capitalist investing in research and development, biotechnology and healthcare. Over the years, Dr. Rosenwald has made great contributions to the world of healthcare research and investing.
Over the course of his impressive 20 year career as an investor and hedge fund manager, Dr. Lindsay A. Rosenwald has been responsible for establishing and re-capitalizing numerous private and public companies within the sectors of biotechnology and life sciences. He has built many profitable, productive relationships over the years with these companies and their founders.
As one of the directors of the Republican Jewish Coalition, Dr. Lindsay Rosenwald also serves as president of Paramount Group Inc., a real estate investment and management firm. He considers one of his greatest accomplishments to be the founding of OpusPoint Partners, LLC located in New York. This relatively new company is committed to identifying and investing in various breakthroughs in healthcare and life science.
Dr. Rosenwald recently negotiated the sale of Cougar Biotechnology Inc. to Johnson & Johnson for nearly $1 billion dollars. Cougar Biotechnology is a development stage biopharmaceutical company that focuses on oncology. The company is currently conducting Phase III trials for a first-in-class compound for late-stage prostate cancer. The drug is called abiraterone acetate.
After only a few years in business, OpusPoint Partners LLC has already made great strides both in the world of investing and medicine. Dr. Lindsay Rosenwald believes that OpusPoint will continue to seek investment opportunities in cutting edge R&D and healthcare companies, searching for start-up businesses and publicly traded companies that will improve the quality of life.
Dr. Rosenwald and the team at OpusPoint Partners utilize their strengths and many years of experience to lead the way in the world of biotechnology and investing. Known as a visionary in these fields, Dr. Rosenwald was the first to invest in a new drug for obesity released in the U.S. market. He also participated in investing in the very first public gene therapy company, and often sees potential for medical breakthroughs that others might miss.
Dr. Lindsay Rosenwald is a graduate of Penn State University with a degree in finance. He received his MD from the Temple University School of Medicine completing his internship at Abington Medical Hospital.
OpusPoint Partners: Breaking Down Barriers in Life Science and Healthcare
Life science and healthcare is emerging into a new phase of innovative development. This development will see a world of better quality medicine and healthcare. OpusPoint Partners strive to be vanguards of this revolutionary shift with real and solid investments into cutting-edge methods. Their vision is to see humanity with greater access to improved healthcare.
With more than 40 years of experience between the two of them, Michael S. Weiss and Dr. Lindsay Rosenwald established OpusPoint Partners in 2009. The company is one of several biotechnology companies the two men have created together, expressing real passion for the field. They have created very solid careers in biotech investment and life science.
Another company started by Dr. Lindsay Rosenwald is Cougar Biotechnology Inc., located in Los Angeles. This company is largely concentrated on conducting experimental research for cancer drugs and has attracted attention from investors and researchers alike. One drug promises good potential for the treatment of prostate cancer in its late states. On July 10, 2009, Johnson & Johnson gained Cougar Biotech Labs for about one billion dollars.
Lindsay Rosenwald and OpusPoint Partners are keenly focused on building alliances with the biotechnology and investment communities. Key to strong relationships is the practice of integrity – part and parcel of an organization’s culture and good business practice. The associations built between companies and industry leaders can benefit from the practice of integrity which ensures honest investment and open and direct disclosures.
OpusPoint Partners and Lindsay Rosenwald are teaming up with researchers, investors and corporations to form a partnership of mutual support and to seek out the same interests in disease treatment that is groundbreaking. Dr. Lindsay Rosenwald and OpusPoint Partners will look for and invest in the most hopeful research companies on the verge of making big medical discoveries.
Dr. Lindsay Rosenwald and OpusPoint Partners plan to change the nature of biotech investing. They are insisting that biotech facilities adhere to high standards of morality and ethical business practices. They are showing, by example, that with these high standards, companies can achieve fruitful rewards without ignoring their responsibilities to good quality.
And Dr. Rosenwald is not a stranger to these practices. He was a biotechnology entrepreneur for over 17 years on Wall Street. He has also been an important player in the founding and recapitalization of several life science and biotech companies. He holds two degrees, one a B.S. in Finance from Pennsylvania State University and the other an M.D. from Temple University School of Medicine.
He has plenty of experience in large-scale financial investing. From 1994 to 2007, he managed The Aries Funds and from 2002 to 2006 he managed the Orion Fund. The Aries Funds invested over $1 billion dollars in healthcare; the Orion Fund contributed funds totally to private biotechnology investments, particularly PIPEs.
OpusPoint Partners’ is founded upon the aim of creating meaningful partnerships in the world of life science and healthcare. These partnerships reflect a mutual dedication to honesty and integrity. In today’s market, this kind of conglomeration may be a rarity, as business leaders may all too often neglect ethics in their goals of obtaining positive clinical trials and higher profit.
But OpusPoint Partners plans to provide an altogether different example. It has already shown its commitment to business integrity in the treatment of its shareholders (particularly to investors and employees). It has also shown its steady stance in applying ethical integrity to the process of drug testing, manufacture and investigation.
Guided by two very competent and successful leaders, OpusPoint Partners undoubtedly has a brilliant future. The shared experience, knowledge and expertise between Michael Weiss and Dr. Lindsay Rosenwald make the two leaders more than apt in guiding the company towards revolutionary change in healthcare and medicine.
It will not be easy, though, to alter traditional attitudes to medicine and healthcare. The collective effort will require time and money well-spent and a great deal of dedication and commitment to firm ethical boundaries.
Dr. Rosenwald, though, knows this is possible. OpusPoint Partners, in a small amount of time, has made important accomplishments. It has managed to help finance more than 20 companies in less than two years. It is clear that using the best practices can certainly produce attractive and ideal results in financing and drug research.
Dr. Lindsay Rosenwald serves the Republican Jewish Coalition as one of its board directors. He also maintains strong associations with leaders in the biotechnology financing industry. OpusPoint Partners looks forward to a progressive future under his leadership guidance.